Autolomous enables cell & gene therapy (CGT) developers and manufacturers to deliver personalized medicine treatments to more patients worldwide. We provide them with ways to scale their operations by deploying a fully integrated and digitized platform, autoloMATE, which allows customers to book, make and deliver CGT treatments. Using our intuitive solutions, CGT manufacturers can eliminate 92% of errors and save 65% of QA resources across end-to-end quality document review and release processes - making operations more compliant, safer and more cost-effective. Our clients span Academia, CDMOs and Bio-Techs across the US, UK, and Europe.